| ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events. | |
| | |
MedLine Citation:
|
PMID: 9779028 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To demonstrate the superiority of enoxaparin compared with unfractionated heparin (UFH) in preventing recurrent angina, myocardial infarction (MI) and death in patients presenting with unstable angina or non-Q wave MI. DESIGN: A prospective, randomized, double-blind multicentre trial. SETTING: One hundred and seventy-six centers in 10 countries. PATIENTS: Three thousand one hundred and seventy-one patients, male or nonpregnant females, 18 years of age or older, with unstable angina or non-Q wave MI. INTERVENTION: Patients received either enoxaparin 1 mg/kg every 12 h subcutaneously plus an intravenous placebo, or subcutaneous placebo injections and UFH as a continuous intravenous infusion. All patients received 100 mg to 325 mg of acetylsalicylic acid daily. Study treatment was administered for 48 h to 8 days. MAIN RESULTS: The primary end-point (recurrent angina, MI or death) was significantly lower in the enoxaparin group compared with the UFH group (16.6% versus 19.8%; P = 0.02) after 14 days and remained significant after 30 days. The need for coronary revascularization was significantly lower for patients assigned to enoxaparin (27.0% versus 32.2%; P < 0.01) after 30 days. There was no difference in the risk of serious hemorrhage between the two groups, but there was a significantly higher incidence of minor hemorrhagic complications in the enoxaparin group (11.9%) versus 7.2%; P < 0.01). CONCLUSIONS: Enoxaparin significantly reduced the triple end-point of recurrent angina, MI and death at 14 days, with a sustained effect at 30 days. There was no increase in the total number of hemorrhages; however, a significant increase in the rate of minor hemorrhage was observed. |
| | |
Authors:
|
C Demers |
Related Documents
:
|
10378558 - Efficacy and safety of danaparoid sodium (org 10172) in critically ill patients with he... 16460638 - Surgical treatment of varicose veins: effect of rationing. 3627708 - Heparin prophylaxis for intraocular fibrin. 3377618 - Deep vein thrombosis after hip surgery among thai. 3597478 - Total hip arthroplasty in paget's disease. a follow-up note. 23571658 - Changes in physical activity and related functional and disability levels in the first ... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: The Canadian journal of cardiology Volume: 14 Suppl E ISSN: 0828-282X ISO Abbreviation: Can J Cardiol Publication Date: 1998 Aug |
Date Detail:
|
Created Date: 1998-10-22 Completed Date: 1998-10-22 Revised Date: 2008-04-09 |
Medline Journal Info:
|
Nlm Unique ID: 8510280 Medline TA: Can J Cardiol Country: CANADA |
Other Details:
|
Languages: eng Pagination: 15E-19E Citation Subset: IM |
Affiliation:
|
Department of Hematology, Centre Hospitalier Affilié, Université Laval, Québec. paradem@mediom.qc.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Angina, Unstable / drug therapy*, prevention & control Double-Blind Method Enoxaparin / pharmacology, therapeutic use* Female Fibrinolytic Agents / pharmacology, therapeutic use* Heparin, Low-Molecular-Weight / pharmacology, therapeutic use* Humans Male Middle Aged Myocardial Infarction / drug therapy*, prevention & control Prospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Enoxaparin; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Approaches to the treatment of unstable angina and non-Q wave myocardial infarction.
Next Document: Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.